Stephen Hursting, PhD, MPH
- Early exposure to a high fat/high sugar diet increases the mammary stem cell compartment and mammary tumor risk in female mice.
- Signals from the adipose microenvironment and the obesity-cancer link: A systematic review.
- Favorable Modulation of Benign Breast Tissue and Serum Risk Biomarkers Is Associated with >10% Weight Loss in Postmenopausal Women
- Calorie restriction and cancer prevention: a mechanistic perspective
- Effects of Calorie Restriction and Diet-Induced Obesity on Murine Colon Carcinogenesis, Growth and Inflammatory Factors, and MicroRNA Expression
- Calorie restriction decreases murine and human pancreatic tumor cell growth, nuclear factor-κB activation, and inflammation-related gene expression in an insulin-like growth factor-1-dependent manner
- NSAID use reduces breast cancer recurrence in overweight and obese women: role of prostaglandin-aromatase interactions
- Associations between time spent sitting and cancer-related biomarkers in postmenopausal women: an exploration of effect modifiers
- Biodistribution and in vivo activities of tumor-associated macrophage-targeting nanoparticles incorporated with Doxorubicin
- Obesity-associated systemic interleukin-6 promotes pre-adipocyte aromatase expression via increased breast cancer cell prostaglandin E2 production
Dr. Hursting earned a BA in biology from Earlham College and a PhD in nutritional biochemistry and an MPH in nutritional epidemiology from the University of North Carolina at Chapel Hill. He also completed postdoctoral training in molecular biology and cancer prevention as a Cancer Prevention Fellow at the National Cancer Institute (NCI). From 1995 to 1999, Dr. Hursting was an Assistant Professor in the Departments of Epidemiology and Carcinogenesis at the University of Texas MD Anderson Cancer Center, where he directed a multidisciplinary research program in nutrition and cancer prevention. He continues his affiliation with his former departments at the MD Anderson Cancer Center as a Professor of Carcinogenesis and Adjunct Associate Professor of Epidemiology.
From 1999-2005, Dr. Hursting was Deputy Director of the NCI’s Office of Preventive Oncology, Division of Cancer Prevention. He was responsible for all aspects of the NCI’s Cancer Prevention Fellowship Program. Dr. Hursting was also an Investigator in the NCI’s Center for Cancer Research, where he was Chief of the Nutrition and Molecular Carcinogenesis Section of the NCI’s Laboratory of Biosystems and Cancer. His research program focuses on the nutritional modulation of the carcinogenesis process, with a particular emphasis on the molecular, cellular and hormonal changes underlying important nutrition and cancer associations, with a focus on energy balance/obesity.
Here you can create the content that will be used within the module.
Research Technician, Hursting Labjodyalb@email.unc.edu
Jody Albright, a former business owner from Salisbury, is a 2011 graduate of Rowan-Cabarrus Comunity College with AS and AAS in Biotechnology degrees. He has recently joined the NRI in Dr. Bennett's lab as a laboratory technician. Jody is excited to use his recent education to develop several new protocols for the laboratory .
Research Technician, Hursting Labjohn_kluttz@unc.edu
John graduated from RCCC in 2010 and has worked in pharmaceuticals for the past 8 years. He has been involved in clinical research for potential HIV treatments, immunotherapies for various cancers, and has gained experience in method development, quality control, and technical writing. He moved back to North Carolina in the summer of 2018 and has begun rebuilding his rabbit farm.
Melissa VerHague, PhD
Research Associate, Hursting Labmelissa_verhague@unc.edu
Melissa VerHague earned her PhD in molecular pathology from Wake Forest University. Her dissertation investigated the impact of apolipoprotein A-IV on triglyceride secretion and lipoprotein particle expansion associated with hepatic steatosis. A native of Buffalo, NY, she joined the NRI as a postdoctoral research associate in September of 2014. Her primary research focus is understanding the role of CD44 in atherosclerosis and metabolic syndrome.